Dabrafenib e trametinib in pazienti con carcinoma anaplastico con mutazione BRAF V600E: update dei risultati dello studio basket di fase II ROAR
Crossref DOI link: https://doi.org/10.1007/s40619-022-01083-8
Published Online: 2022-05-26
Published Print: 2022-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Castagna, Maria Grazia
Funding for this research was provided by:
Università degli Studi di Siena
Text and Data Mining valid from 2022-05-26
Version of Record valid from 2022-05-26
Article History
Accepted: 31 January 2022
First Online: 26 May 2022